Entegris, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; includes fourth-quarter results. Entegris supplies advanced materials and process solutions for semiconductor and other high-technology manufacturing. Its four segments are Specialty Chemicals and Engineered Materials (SCEM), Microcontamination Control (MC), Advanced Materials Handling (AMH), and Advanced Planarization Solutions (APS).
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net sales | $3,282.0 million | $2,298.9 million |
| Gross profit / gross margin | $1,396.4 million / 42.5% | $1,059.7 million / 46.1% |
| Operating income / margin | $480.0 million / 14.6% | $551.8 million / 24.0% |
| Net income | $208.9 million | $409.1 million |
| Diluted EPS | $1.46 | $3.00 |
| Operating cash flow | $352.3 million | $400.5 million |
| Capital expenditures | $466.2 million | $210.6 million |
Fourth-quarter 2022 sales were $946.1 million and net income was $57.4 million ($0.38 diluted EPS), versus $635.2 million and $118.2 million ($0.87 diluted EPS), respectively, in fourth-quarter 2021. Third-quarter 2022 included a net loss of $73.7 million.
Cash, cash equivalents and restricted cash totaled $563.4 million at year-end; working capital was $1,573.3 million. Debt was $5,784.9 million net of discounts and issuance costs ($5,925.0 million principal value). The $575 million revolving facility had no year-end borrowings, apart from $1.5 million in undrawn letters of credit. The company reported compliance with applicable debt covenants.
Adjusted EBITDA, a non-GAAP measure, was $973.2 million (29.7% of sales), compared with $699.4 million (30.4%) in 2021. Adjusted operating income was $837.9 million (25.5% of sales), and non-GAAP EPS was $3.73. These measures exclude specified costs and should be considered alongside GAAP results.
Material changes versus the prior year
- Sales increased 43%, reflecting $495.6 million of acquired-business sales, $594.4 million of growth excluding acquired businesses, and a $106.9 million adverse foreign-exchange impact.
- CMC Materials was acquired on July 6, 2022, for a total purchase price of approximately $6.0 billion. It contributed $581.0 million of post-acquisition sales and a $75.8 million net loss. Its inclusion makes year-over-year comparisons less like-for-like.
- Gross margin fell 3.6 percentage points, in part due to a $61.9 million charge for the fair-value write-up of acquired inventory sold and the acquired business’s lower aggregate gross margins. Operating income and GAAP net income declined despite higher sales.
- Interest expense increased to $212.7 million from $41.2 million, primarily due to acquisition financing. SG&A rose to $543.5 million, including acquisition transaction and integration costs. Amortization increased to $144.0 million, largely reflecting acquired intangible assets.
- Operating cash flow declined $48.2 million; higher inventory and capital spending weighed on cash generation. Investing cash outflow included $4,474.9 million, net of acquired cash, for the CMC acquisition.
- Year-end inventory increased to $812.8 million from $475.2 million, with management citing higher purchases to mitigate supply-chain risk and increased business activity.
Segment snapshot
| Segment | FY2022 sales | FY2022 segment profit | Year-over-year context |
|---|---|---|---|
| SCEM | $773.6 million | $122.3 million | Sales up 24%; profit down 11%. |
| MC | $1,106.0 million | $411.5 million | Sales up 20%; profit up 28%. |
| AMH | $846.5 million | $183.7 million | Sales up 20%; profit up 15%. |
| APS | $606.6 million | $96.9 million | Increase largely reflects CMC Materials. |
Outlook, risks and unusual items
- Management estimated that U.S. export controls announced in October 2022 would reduce 2023 net sales by approximately $20 million per quarter; it intended to seek licenses where appropriate.
- Management expected 2023 capital expenditures of approximately $500 million, mainly for growth capacity and facilities in Taiwan and Colorado. It also expected R&D expense as a percentage of revenue to increase in coming years. No broader quantified earnings or sales guidance is provided in the supplied filing text.
- Management stated existing domestic cash and expected operating cash flows should cover ordinary-course needs for the next twelve months and longer term. The company nonetheless faces substantial debt service, variable-rate exposure, restrictive covenants, and refinancing and liquidity risks. A swap hedged $1.95 billion of term-loan exposure through December 2025.
- Key operating risks include semiconductor cyclicality, supply constraints and single-source suppliers, customer concentration (top ten represented 43% of sales; TSMC 12%), international exposure (76% of sales), China-related trade restrictions, integration execution, and foreign-exchange movements. China represented approximately 15% of 2022 sales.
- The agreement to sell the PIM business for $240 million was terminated on February 10, 2023, after antitrust clearance was not obtained; the related assets and liabilities had been classified as held for sale at year-end. The company said it would reassess that classification. A QED sale agreement for approximately $135 million was announced in January 2023, subject to customary conditions and regulatory approval.
- The filing identifies ongoing intellectual-property litigation involving Gudeng and DuPont, while stating that known legal matters were not considered reasonably likely to involve a material loss. It also discloses uncertainty around tax positions and other contingencies.
- The financial-statement audit opinion was unqualified, and management and KPMG concluded internal control over financial reporting was effective. CMC Materials’ controls, covering $6.54 billion of assets and $581.0 million of sales, were excluded from the year-end ICFR assessment during integration.
Important facts for investors to verify
- How much of reported growth and future performance is attributable to CMC Materials versus underlying organic demand, and whether integration benefits offset acquired costs and lower gross margins.
- The pace of debt reduction, bridge-facility repayment and interest costs, including the effect of rates on unhedged variable-rate debt and the terms of covenants.
- The actual sales impact of China export controls relative to management’s estimate of approximately $20 million per quarter in 2023.
- Whether inventory levels normalize and whether elevated capital spending converts into productive capacity, cash generation and returns.
- The status and financial consequences of the terminated PIM sale and proposed QED sale, along with the ongoing intellectual-property litigation and tax contingencies.